Literature DB >> 12119452

Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists.

Jean-Pierre Raufman1, Ying Chen, Piotr Zimniak, Kunrong Cheng.   

Abstract

In the course of examining the actions of major human bile acids on cholinergic receptors, we discovered that conjugates of lithocholic acid are partial muscarinic agonists. In the present communication, we report that conjugates of deoxycholic acid (DC) act as cholinergic muscarinic receptor antagonists. Chinese hamster ovary (CHO) cells expressing rat M3-muscarinic receptors were used to test bile acids for inhibition of radioligand [N- (3)H-methylscopolamine ((3)H-NMS)] binding; alteration of inositol phosphate (IP) formation; mitogen-activated protein (MAP) kinase phosphorylation and cell toxicity. We observed approximately 18.8, 30.3 and 37.1% inhibition of (3)H-NMS binding with DC and its glycine (DCG) and taurine (DCT) conjugates, respectively (all 100 micromol/l, p < 0.01). DCT and DCG inhibited acetylcholine-induced increases in IP formation and MAP kinase phosphorylation (p44 and p42 ERK). DCG and DCT did not alter trypan blue exclusion or lactate dehydrogenase release from CHO-M3 cells. We observed the following rank order of potency (IC(50) micromol/l) for inhibition of (3)H-NMS by muscarinic antagonists and bile acids: NMS (0.0004) > 4-DAMP (0.009) > atropine (0.012) > DCT (170) > DCG (250). None of the bile acids tested were hydrolyzed by recombinant cholinesterase. At concentrations achieved in human bile, DC derivatives are natural muscarinic antagonists. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12119452     DOI: 10.1159/000064347

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  16 in total

Review 1.  Muscarinic receptors and ligands in cancer.

Authors:  Nirish Shah; Sandeep Khurana; Kunrong Cheng; Jean-Pierre Raufman
Journal:  Am J Physiol Cell Physiol       Date:  2008-11-26       Impact factor: 4.249

Review 2.  Bile acids regulate cardiovascular function.

Authors:  Sandeep Khurana; Jean-Pierre Raufman; Thomas L Pallone
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

3.  Bile Acid Receptors and Gastrointestinal Functions.

Authors:  Alexander L Ticho; Pooja Malhotra; Pradeep K Dudeja; Ravinder K Gill; Waddah A Alrefai
Journal:  Liver Res       Date:  2019-01-14

Review 4.  GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation.

Authors:  T Lieu; G Jayaweera; N W Bunnett
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 5.  The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation.

Authors:  Thijs W H Pols; Lilia G Noriega; Mitsunori Nomura; Johan Auwerx; Kristina Schoonjans
Journal:  J Hepatol       Date:  2010-12-09       Impact factor: 25.083

Review 6.  The bile acid membrane receptor TGR5: a valuable metabolic target.

Authors:  Thijs W H Pols; Lilia G Noriega; Mitsunori Nomura; Johan Auwerx; Kristina Schoonjans
Journal:  Dig Dis       Date:  2011-06-17       Impact factor: 2.404

Review 7.  Activation of muscarinic receptor signaling by bile acids: physiological and medical implications.

Authors:  Jean-Pierre Raufman; Kunrong Cheng; Piotr Zimniak
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

Review 8.  Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.

Authors:  Petra Mamic; Thanat Chaikijurajai; W H Wilson Tang
Journal:  J Mol Cell Cardiol       Date:  2020-12-09       Impact factor: 5.000

9.  Effects of deoxycholylglycine, a conjugated secondary bile acid, on myogenic tone and agonist-induced contraction in rat resistance arteries.

Authors:  Sandeep Khurana; Hema Raina; Valeria Pappas; Jean-Pierre Raufman; Thomas L Pallone
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

10.  Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod.

Authors:  Ronald Mathison; Eldon Shaffer
Journal:  BMC Gastroenterol       Date:  2006-02-23       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.